文献速递衰弱、肌少症与跌倒多重用药

多重用药与社区队列中衰弱新发的关联研究

Polypharmacy and Incident Frailty in a Longitudinal Community-Based Cohort Study.
PubMed 文献 · J Am Geriatr Soc · 2019-10-24

该前瞻性队列纳入美国北卡罗来纳州Johnston县50至95岁白人与非裔成年人1697名,在2006-2010年访视时评估多重用药(5-9种药物)与过度多重用药(≥10种药物)暴露,并追踪至2013-2015年访视评估Fried衰弱表型。结果显示多重用药与衰弱新发呈正相关(加权RR=1.4;

要点

  • 2006-2010年访视时,41%参与者存在多重用药(5-9种药物),16%存在过度多重用药(≥10种药物)。
  • 2013-2015年访视时衰弱新发为15%(平均随访5.5年)。

核心结论

  • 与现有证据总体一致,结果提示多重用药与衰弱新发存在关联。
  • 需要前瞻性研究评估减药干预能否降低衰弱发生率。

研究设计与样本

  • 前瞻性队列研究,纳入美国北卡罗来纳州Johnston县社区居住的50至95岁白人与非裔成年人1697名。
  • 在2006-2010年访视记录所有处方药与非处方药,计算多重用药(5-9种)与过度多重用药(≥10种)的年患病率。
  • 采用Fried衰弱表型在2006-2010年与2013-2015年连续两次访视评估现患与新生衰弱。
  • 使用加权对数二项回归估计风险比(RR)及95%置信区间(CI),并分别采用治疗概率权重与失访概率权重校正可测量混杂与失访。

主要发现

  • 2006-2010年访视时,678名(41%)参与者暴露于多重用药,260名(16%)暴露于过度多重用药。
  • 2006-2010年访视时353名(21%)参与者衰弱,2013-2015年访视时180名(21%)参与者衰弱。
  • 相对于不具备相应特征者,衰弱在白人、女性及受教育程度较低的参与者中更常见。
  • 2013-2015年访视时衰弱新发为15%(平均随访5.5年)。

关键数值与推荐

  • 多重用药定义为5-9种药物,过度多重用药定义为≥10种药物。
  • 衰弱采用Fried衰弱表型定义。

临床怎么用

  • 在老年患者中应记录全部处方药与非处方药,识别多重用药(5-9种)与过度多重用药(≥10种)。
  • 对多重用药患者可关注衰弱风险,但现有估计不精确,尚不能据此断定减药可降低衰弱发生率。
  • 需前瞻性减药干预研究来明确减少多重用药是否降低衰弱发生率。

局限性

  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Polypharmacy may affect frailty, a common and costly condition among older adults. Frailty prevalence is elevated among racial/ethnic minorities and persons living in the US South, and research is needed to inform future pharmacologic interventions in these populations. Our aim was to quantify the prevalence of frailty and polypharmacy, and to estimate the association between polypharmacy and incident frailty. DESIGN: Prospective cohort study. SETTING: A community-based cohort study of adults residing in Johnston County, North Carolina. PARTICIPANTS: White and African American adults aged 50 to 95 years (n=1697). MEASUREMENTS: At each study visit, all prescription and over-the-counter medications were recorded. We calculated annual polypharmacy (5-9 medications) and excessive polypharmacy (≥10 medications) prevalence at the 2006-2010 visit (n = 1697) and operationalized the Fried frailty phenotype to describe prevalent and incident frailty at two consecutive visits (2006-2010 and 2013-2015). We estimated risk ratios (RRs) and 95% confidence intervals (CIs) for the association between polypharmacy and incident frailty using weighted log-binomial regression to account for measured confounding and attrition using inverse probability of treatment and attrition weights, respectively. RESULTS: At the 2006-2010 visit, 678 (41%) and 260 (16%) participants were exposed to polypharmacy and excessive polypharmacy, respectively. Overall, 353 (21%) participants and 180 (21%) participants were frail at the 2006-2010 and 2013-2015 visits, respectively. Frailty was more common among participants identifying as white, women, and having less educational attainment relative to those without these characteristics. Incident frailty at the 2013-2015 visit was 15% (mean follow-up = 5.5 years). Our results suggest that polypharmacy is positively associated with incident frailty (weighted RR = 1.4; 95% CI = .9-2.0), yet estimates are imprecise and should be interpreted with caution. CONCLUSION: Consistent with the current weight of evidence, our results suggest an association between polypharmacy and incident frailty. Prospective studies evaluating deprescribing interventions are needed to clarify whether reducing polypharmacy decreases frailty incidence. J Am Geriatr Soc 67:2482-2489, 2019.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Shmuel S, Lund JL, Alvarez C, et al. Polypharmacy and Incident Frailty in a Longitudinal Community-Based Cohort Study. J Am Geriatr Soc. 2019. PMID: 31648378. doi:10.1111/jgs.16212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。